Role of quinagolide (NORPROLAC) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients

M Alhalabi,S Samawi,N Kafri,J Sharif,A Saker,A Othman

doi:10.1016/j.fertnstert.2012.07.378

Role of quinagolide (NORPROLAC) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients

M Alhalabi, S Samawi + Show 4 more

Open Access

https://doi.org/10.1016/j.fertnstert.2012.07.378

Copy DOI

Journal: Fertility and Sterility	Publication Date: Aug 25, 2012
License type: elsevier-specific: oa user license

Affiliation: Damascus Hospital, Damascus University

#Ovarian Hyperstimulation Syndrome #Ferring Pharmaceuticals + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

OHSS appears to be induced by the ovarian release vascular endothelial growth factor (VEGF) and its receptor 2 (VEGFR2), causing increase vascular permeability (VP). Dopamine agonist (DA) inhibit VEGF/VEGFR2 and thereby decrease VP. The aim of this study was to determine the efficacy of non-ergot derived Dopamine agonist Quinagolide (Norprolac: Ferring Pharmaceuticals) in preventing OHSS in high risk women undergoing ICSI, and how would it affect the outcome?

Full Text